License and Collaboration Agreements - Additional Information (Details) - USD ($) $ in Thousands		12 Months Ended
	Jun. 11, 2021	Dec. 31, 2021	Dec. 31, 2020
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront payment received		$ 625,000
License revenue		344,775
Revenue From Contract With Customer Including Assessed Tax		344,775
Contract with Customer, Liability		280,225
Adimab L L C
Research And Development Arrangement Contract To Perform For Others [Line Items]
Maximum additional receivable based on achievement of research milestones		14,500	$ 1,000
Adimab L L C | License revenue
Research And Development Arrangement Contract To Perform For Others [Line Items]
License revenue		3,400
Revenue From Contract With Customer Including Assessed Tax		3,400
Adimab L L C | Development Regulatory and Sales Milestone
Research And Development Arrangement Contract To Perform For Others [Line Items]
Maximum option fees receivable based on achievement of research milestones		45,800
GSK
Research And Development Arrangement Contract To Perform For Others [Line Items]
Upfront payment received	$ 625,000
Milestone payments	$ 1,450,000
Eligible royalty payments percentage	20.00%
Contract with Customer, Liability		280,200
Cost Share Costs Incurred For License Agreement		11,500
Capitalized contract cost, net		$ 6,800
Costs related to global development plan		60.00%
Payment for license agreement reimbursement of costs incurred		$ 4,800
Due to related parties		3,000
Related party transaction, expenses from transactions with related party		900,000
GSK | License revenue
Research And Development Arrangement Contract To Perform For Others [Line Items]
License revenue		344,800
Revenue From Contract With Customer Including Assessed Tax		$ 344,800